The rise of copyright’s blockbuster initially drove a boom for pharma, but recent developments present a murky scenario for investors. Off-patent competitors are reducing earnings, and continued litigation add additional complexity to the equation. While some companies may still benefit from related services, the general direction suggests a mea… Read More